Literature DB >> 22202584

Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies.

Shigeki Kusamura1, Dario Baratti, Marcello Deraco.   

Abstract

OBJECTIVE: To evaluate the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating peritoneal surface malignancies (PSM). SUMMARY AND
BACKGROUND: CRS and HIPEC to treat PSM is a complex procedure with a significant morbidity. A long-lasting training program is required to acquire expertise in this type of operation.
METHODS: We performed CRS using peritonectomy procedures. HIPEC through the closed abdomen technique employed cisplatin and mitomycin-C or cisplatin and doxorubicin. Risk-adjusted sequential probability ratio test was used to assess the learning curve on a series of 420 cases of PSM on the basis of rates of incomplete cytoreduction and G3-5 morbidity (NCI-CTCAE v3). We determined control limits setting the type I/II error rates and unacceptable odds ratios (ORs) for the outcomes being studied. We performed the risk adjustment using logistic regression model.
RESULTS: Rates of incomplete cytoreduction, G3-5 morbidity, and postoperative mortality rates were 10.2%, 28.5%, and 2.1%, respectively. The risk-adjusted sequential probability ratio test curve crossed the lower control limit at the 137 th and 149 th case, respectively, for incomplete cytoreduction and G3-5 morbidity. At those points, the actual ORs are lower than the prespecified ORs for outcomes being studied. Therefore, we estimated that approximately 140 cases are necessary to ensure surgical proficiency in CRS and HIPEC.
CONCLUSIONS: CRS and HIPEC to treat PSM has a steep learning curve requiring 140 procedures to acquire expertise.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22202584     DOI: 10.1097/SLA.0b013e3182436c28

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  30 in total

Review 1.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ramakrishnan Ayloor Seshadri; Olivier Glehen
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

2.  Establishing of Peritoneal Surface Malignancy Treatment Program: Background in Ukraine, Patient Selection, Staff Schedule, Perioperative Outcomes of First 28 Patients.

Authors:  V I Kopetskyi; K V Kopchak; D O Cheverdiuk; O O Kvasivka; A P Beznosenko; O O Kolesnik; V V Gushchin
Journal:  Indian J Surg Oncol       Date:  2020-03-16

3.  High-quality results of cytoreductive surgery and heated intraperitoneal chemotherapy perfusion for carcinomatosis at a low volume institution.

Authors:  Swaroop R Bommareddi; Vlad V Simianu; Lisa V Mann; Gary N Mann
Journal:  J Surg Oncol       Date:  2015-08-14       Impact factor: 3.454

Review 4.  Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise.

Authors:  Ramez N Eskander; James Cripe; Robert E Bristow
Journal:  Curr Treat Options Oncol       Date:  2014-03

5.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.

Authors:  Ayman Zaki Azzam; Zyad Adil Alyahya; Ahmed Abbas Al Wusaibie; Tarek Mahmoud Amin
Journal:  Indian J Gastroenterol       Date:  2017-11-29

6.  Comparison of the outcomes of cytoreductive surgery versus surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: a propensity score matching analysis.

Authors:  Zhou Li; Juan de Dios Redondo Ntutumu; Shengyi Huang; Zhai Cai; Shuai Han; A I Balde; Zeyu Luo; Suzhen Fang
Journal:  Surg Endosc       Date:  2020-07-06       Impact factor: 4.584

Review 7.  Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion.

Authors:  Rahul Rajeev; Brittany Klooster; Kiran K Turaga
Journal:  J Gastrointest Oncol       Date:  2016-02

8.  CRS and HIPEC for PMP-Use of the LC-CUSUM to Determine the Number of Procedures Required to Attain a Minimal Level of Proficiency in Delivering the Combined Modality Treatment.

Authors:  Aditi Bhatt; Antony George; Sanket Mehta
Journal:  Indian J Surg Oncol       Date:  2017-08-12

Review 9.  Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Zhong-He Ji; Kai-Wen Peng; Yan Li
Journal:  Transl Gastroenterol Hepatol       Date:  2016-09-19

10.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?

Authors:  V López-López; P A Cascales-Campos; E Gil; J Arevalo; A Gonzalez; J Gil; F C Muñoz-Casares; J T Melero; P Barrios; R Morales; I Ramos; G Ortega; B Camps; L González-Bayón; P Bretcha-Boix; J Farré-Alegre; S González-Moreno; P Parrilla
Journal:  Clin Transl Oncol       Date:  2017-08-10       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.